======================================

제  목 :  FROM ORGANIC CHEMISTRY TO MOLECULAR IMAGING: FUTURECHEM

연  사 :  지대윤 교수님(서강대학교 화학과)

일  시 :  2018년 11월 8일(목) 오후 4시 15분   
장  소 :  화학관 1층 첨단강의실(330118호)

--------------------------------------   

I. NEW FLUORINATION METHOD IN A NONPOLAR PROTIC ALCOHOL SOLVENTS

The typical method for introducing fluorine, which is the best PET radioisotope, at a specific aliphatic molecular site is the nucleophilic displacement of the corresponding sulfonate or halide by fluoride ion. Ten years ago, we have developed a remarkable effect of using tertiary alcohols as a reaction medium for nucleophilic fluorination with alkali metal fluorides. The great efficacy of this method is a particular advantage in labeling radiopharmaceuticals with [¹⁸F]fluorine in high yield and purity, and in shorter times compared to conventional syntheses. In this new mechanism, the bulky, polarizable cation separates F^- from the protic solvent, which in turn acts as a base to reduce the unfavorable influence of the cation on the nucleophilicity of F^-.

II. NEW PET RADIOPHARMACEUTICALS IN MARKET

After FDG has been used since 1980s commercially, new F-18 labeled commercial PET radiopharmaceuticals have not been lunched until 2008. Using this new fluorination method, two new radiopharmaceuticals [¹⁸F]FLT (cell proliferation imaging) and [¹⁸F]FP-CIT³ (Parkinson disease) were registered at Korea FDA in 2008. For your information, [¹⁸F]FLT and [¹⁸F]FP-CIT are commercially used for patients at Korea after getting the official permission from Korean FDA in 2008 spring. In 2002, ¹¹C-labeled [¹¹C]PIB (Pittsburgh compound B) was developed for imaging Aβ plaque in the brain of living subjects by modifying Thioflavin T, which has been used as a fluorescent dye for staining Aβ plaque in postmortem brains. [¹¹C]PIB exhibited good Aβ plaque binding in a living brain with an appropriate brain accumulation and washout ratio. Three F-18 labeled PET tracers have been approved by the U.S. Food and Drug Administration (FDA) in 2012 (Amyvid^TM, Eli Lilly), 2013 (Vizamyl^TM, GE Healthcare), and 2014 (Neuraceq^TM, Piramal) as Aβ imaging agents and a secondary tool for the diagnosis of AD. We have also developed fourth F-18 labeled Aβ imaging PET tracer in NDA by Korean FDA in 2018 (Alzavue^®, FutureChem). Prostate cancer imaging including some therapeutics will be discussed.

III. DEVELOPEMNT OF NEW ORGANIC SYNTHESIS METHODOLOGIES

Some new organic synthesis methodologies will be discussed.